Figure 8
From: Figures in clinical trial reports: current practice & scope for improvement
Kaplan-Meier Estimates of the Cumulative Incidence of Monotherapy Failure at 5 Years. Treatment was considered to have failed if a patient had a confirmed or adjudicated level of fasting plasma glucose of more than 180 mg per deciliter. Risk reduction is listed for comparisons of pairwise groups from a baseline covariate-adjusted Cox proportional-hazards model. Gray's estimates of cumulative incidence adjusted for all deaths were smaller than Kaplan-Meier estimates of treatment failure: 10% in the rosiglitazone group, 15% in the metformin group, and 25% in the glyburide group. I bars indicate 95% CIs. (Kahn et al. NEJM Dec 7, 2006 p2433)